Minimal Residual Disease Assessed in AL Amyloidosis Patients
|
By LabMedica International staff writers Posted on 17 Mar 2020 |
|
Image: The Gallios flow cytometer provides efficient acquisition of superior quality data from up to 10 colors with advanced optical design for enhanced sensitivity for multicolor assays (Photo courtesy of Beckman Coulter).
Amyloid light-chain (AL) amyloidosis, also known as primary amyloidosis, is the most common form of systemic amyloidosis in the USA. Despite achieving a hematologic complete response after treatment, many patients with AL amyloidosis do not attain recovery of organ function and/or experience hematologic relapse.
A persistent plasma cell clone producing amyloidogenic light chains at levels below the detection threshold of traditional serologic methods is hypothesized to impede organ response in some patients. Assessment of minimal residual disease (MRD) may therefore have clinical importance as a more stringent treatment response tool for patients in a hematologic complete response.
Hematologists at the Boston University School of Medicine (Boston, MA, USA) evaluated a total of 86 patients with AL amyloidosis with hematologic complete response (hemCR) achievement on previous evaluation were tested for MRD. Fresh bone marrow aspirate samples from consenting patients with AL amyloidosis were analyzed between February and November 2019. The scientists used 2-tube, 10-color antibody combination multiparametric flow cytometry to assess for MRD at a minimum sensitivity of 1 in 105 nucleated cells. Specimen processing was performed at PhenoPath Laboratories (Seattle, WA, USA) with a target of two million live cellular events acquired on a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA).
The scientists reported that of 65 patients in hematologic complete response, 36 (55%) were found to have a residual clonal plasma cell population in the bone marrow. Comparing the MRD-negative and MRD-positive groups, renal response was observed in 88% versus 64%, cardiac response in 75% versus 59%, and any organ response in 90% versus 75% of patients. Depth of organ response as measured by the percent decrease in 24-hour proteinuria and brain natriuretic peptide was 96% versus 91% and 55% versus 46%, respectively. Notably, the median difference between involved and uninvolved serum free immunoglobulin light chain (dFLC) at diagnosis was significantly higher in the MRD-negative cohort (129 mg/L versus 70 mg/L).
The authors concluded that MRD negativity as a deeper treatment response classification was correlated with higher organ response in patients with AL amyloidosis in hemCR, although differences were not statistically significant. The study was published on March 4, 2020 in the journal Blood Advances.
Related Links:
Boston University School of Medicine
PhenoPath Laboratories
Beckman Coulter
A persistent plasma cell clone producing amyloidogenic light chains at levels below the detection threshold of traditional serologic methods is hypothesized to impede organ response in some patients. Assessment of minimal residual disease (MRD) may therefore have clinical importance as a more stringent treatment response tool for patients in a hematologic complete response.
Hematologists at the Boston University School of Medicine (Boston, MA, USA) evaluated a total of 86 patients with AL amyloidosis with hematologic complete response (hemCR) achievement on previous evaluation were tested for MRD. Fresh bone marrow aspirate samples from consenting patients with AL amyloidosis were analyzed between February and November 2019. The scientists used 2-tube, 10-color antibody combination multiparametric flow cytometry to assess for MRD at a minimum sensitivity of 1 in 105 nucleated cells. Specimen processing was performed at PhenoPath Laboratories (Seattle, WA, USA) with a target of two million live cellular events acquired on a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA).
The scientists reported that of 65 patients in hematologic complete response, 36 (55%) were found to have a residual clonal plasma cell population in the bone marrow. Comparing the MRD-negative and MRD-positive groups, renal response was observed in 88% versus 64%, cardiac response in 75% versus 59%, and any organ response in 90% versus 75% of patients. Depth of organ response as measured by the percent decrease in 24-hour proteinuria and brain natriuretic peptide was 96% versus 91% and 55% versus 46%, respectively. Notably, the median difference between involved and uninvolved serum free immunoglobulin light chain (dFLC) at diagnosis was significantly higher in the MRD-negative cohort (129 mg/L versus 70 mg/L).
The authors concluded that MRD negativity as a deeper treatment response classification was correlated with higher organ response in patients with AL amyloidosis in hemCR, although differences were not statistically significant. The study was published on March 4, 2020 in the journal Blood Advances.
Related Links:
Boston University School of Medicine
PhenoPath Laboratories
Beckman Coulter
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
8-Channel Pipette
SAPPHIRE 20–300 µL
Capillary Blood Collection Tube
IMPROMINI M3
Latest Hematology News
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
Channels
Clinical Chemistry
view channel
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read more
Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
People with diabetes often need to measure their blood glucose multiple times a day, most commonly through finger-prick blood tests or implanted sensors. These methods can be painful, inconvenient, and... Read more
Molecular Diagnostics
view channel
Urine Test Could Reveal Real Age and Life Span
Chronological age does not always reflect how quickly the body is aging, as biological age is shaped by genetics, stress, sleep, nutrition, and lifestyle factors such as smoking. A higher biological age... Read more
Genomic Test Identifies African Americans at Risk for Early Prostate Cancer Recurrence
Prostate cancer is one of the most commonly diagnosed cancers in men and a leading cause of cancer-related death, particularly in the United States. African American men face a disproportionately higher... Read more
Immunology
view channel
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read more
Microbiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more
Pathology
view channel
Genetics and AI Improve Diagnosis of Aortic Stenosis
Aortic stenosis is a progressive narrowing of the aortic valve that restricts blood flow from the heart and can be fatal if left untreated. There are currently no medical therapies that can prevent or... Read more
AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read moreTechnology
view channel
Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
Detecting cancer early and tracking how it responds to treatment remains a major challenge, particularly when cancer cells are present in extremely low numbers in the bloodstream. Circulating tumor cells... Read more
AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
Colorectal cancer is one of the most common and deadly cancers worldwide, and accurately predicting patient survival remains a major clinical challenge. Traditional prognostic tools often rely on either... Read more
Industry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more
